Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Public Health
Metabolomic Profiles In Breast Cancer: A Pilot Case-Control Study In The Breast Cancer Family Registry, Marcelle Dougan, Yuqing Li, Lisa Chu, Robert Haile, Alice Whittemore, Summer Han, Steven Moore, Joshua Sampson, Irene Andrulis, Esther John, Ann Hsing
Metabolomic Profiles In Breast Cancer: A Pilot Case-Control Study In The Breast Cancer Family Registry, Marcelle Dougan, Yuqing Li, Lisa Chu, Robert Haile, Alice Whittemore, Summer Han, Steven Moore, Joshua Sampson, Irene Andrulis, Esther John, Ann Hsing
Faculty Publications
Background Metabolomics is emerging as an important tool for detecting differences between diseased and non-diseased individuals. However, prospective studies are limited. Methods We examined the detectability, reliability, and distribution of metabolites measured in pre-diagnostic plasma samples in a pilot study of women enrolled in the Northern California site of the Breast Cancer Family Registry. The study included 45 cases diagnosed with breast cancer at least one year after the blood draw, and 45 controls. Controls were matched on age (within 5 years), family status, BRCA status, and menopausal status. Duplicate samples were included for reliability assessment. We used a liquid …
Incidence Of Second Malignancy In Patients With Papillary Thyroid Cancer From Surveillance, Epidemiology, And End Results 13 Dataset, Mayumi Endo, Jessica Liu, Marcelle Dougan, Jennifer Lee
Incidence Of Second Malignancy In Patients With Papillary Thyroid Cancer From Surveillance, Epidemiology, And End Results 13 Dataset, Mayumi Endo, Jessica Liu, Marcelle Dougan, Jennifer Lee
Faculty Publications
Increased risk of second primary malignancy (SPM) in papillary thyroid cancer (PTC) has been reported. Here, we present the most updated incidence rates of second primary malignancy from original diagnosis of PTC by using the data from the Surveillance, Epidemiology, and End Results. In this cohort, 3,200 patients developed SPM, a substantially higher number than in the reference population of 2,749 with observed to expected ratio (O/E) of 1.16 (95% CI; 1.12–1.21). Bone and joint cancer had the highest O/E ratio of 4.26 (95% confidence interval [CI] 2.33–7.15) followed by salivary gland (O/E 4.15; 95% CI 2.76–6.0) and acute lymphocytic …